[1] |
XIE M Q, CHEN R, REN M L. Chinese guidelines for menopausal management and menopausal hormone therapy (2018)[J]. Chin J Obstet Gynecol, 2018, 9(06): 512-25.
|
[2] |
STABILE C, GOLDFARB S, BASER R E, et al. Sexual health needs and educational intervention preferences for women with cancer[J]. Breast Cancer Res Treat, 2017, 165(1): 77-84.
doi: 10.1007/s10549-017-4305-6
|
[3] |
KAGAN R S, KELLOGG-SPADT S, PARISH S J. Practical treatment considerations in the management of genitourinary syndrome of menopause[J]. Drugs Aging, 2019, 36(10): 897-908.
doi: 10.1007/s40266-019-00700-w
pmid: 31452067
|
[4] |
KOZMA B, PÓKA R, SIPOS A, et al. Short-term efficacy of vaginal CO2 laser therapy as a treatment modality for genitourinary syndrome of menopause[J]. Orv Hetil, 2019, 160(41): 1617-1622.
doi: 10.1556/650.2019.31529
|
[5] |
GERNIER F, GOMPEL A, ROUSSET-JABLONSKI C, et al. Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study[J]. Gynecol Oncol, 2021, 163(3): 598-604.
doi: 10.1016/j.ygyno.2021.10.001
pmid: 34649724
|
[6] |
MCNEIL M. Menopausal hormone therapy: understanding long-term risks and benefits[J]. JAMA, 2017, 318(10): 911-913.
doi: 10.1001/jama.2017.11462
pmid: 28898364
|
[7] |
CHLEBOWSKI R T, ANDERSON G L, ARAGAKI A K, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials[J]. JAMA, 2020, 324(4): 369-380.
doi: 10.1001/jama.2020.9482
|
[8] |
CHU K, SONG Y, CHATOOAH N D, et al. The use and discontinuation of hormone replacement therapy in women in South China[J]. Climacteric, 2018, 21(1): 47-52.
doi: 10.1080/13697137.2017.1397622
pmid: 29166793
|
[9] |
WANG X M, CHEN Q Y, HUANG X, et al. Effects of 17β-estradiol and tamoxifen on gastric cancer cell proliferation and apoptosis and ER-α36 expression[J]. Oncol Lett, 2017, 13(1): 57-62.
doi: 10.3892/ol.2016.5424
pmid: 28123522
|
[10] |
CHO H W, CHO H W, OUH Y T, et al. Effects of hormone therapy on recurrence in endometrial cancer survivors: a nationwide study using the Korean Health Insurance Review and Assessment Service database[J]. J Gynecol Oncol, 2019, 30(4): e51.
doi: 10.3802/jgo.2019.30.e51
|
[11] |
LIM S, KIM Y H, LEE K B, et al. The influence of hormone therapy with drospirenone-estradiol on endometrioid type endometrial cancer patients[J]. J Gynecol Oncol, 2018, 29(5): e72.
doi: 10.3802/jgo.2018.29.e72
|
[12] |
DI DONATO V, PALAIA I, D’ANIELLO D, et al. Does hormone replacement therapy impact the prognosis in endometrial cancer survivors? A systematic review[J]. Oncology, 2020, 98(4): 195-201.
doi: 10.1159/000505427
pmid: 32036368
|
[13] |
EDEY K A, RUNDLE S, HICKEY M. Hormone replacement therapy for women previously treated for endometrial cancer[J]. Cochrane Database Syst Rev, 2018, 5: CD008830.
|
[14] |
BRENNAN A, BRENNAN D, REES M, et al. Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer[J]. Int J Gynecol Cancer, 2021, 31(3): 352-359.
doi: 10.1136/ijgc-2020-002032
pmid: 33127864
|
[15] |
Committee of Psoriasis, Dermatology Branch, Chinese Medical Association. Guidelines for the diagnosis and treatment of psoriasis in China: 2019 concise edition #[J]. Int J Dermatol Venereol, 2020, 3(1): 14-26.
doi: 10.1097/JD9.0000000000000074
|
[16] |
EELES R A, MORDEN J P, GORE M, et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial[J]. J Clin Oncol, 2015, 33(35): 4138-4144.
doi: 10.1200/JCO.2015.60.9719
pmid: 26417001
|
[17] |
SAEAIB N, PEEYANANJARASSRI K, LIABSUETRAKUL T, et al. Hormone replacement therapy after surgery for epithelial ovarian cancer[J]. Cochrane Database Syst Rev, 2020, 1: CD012559.
|
[18] |
LI D, DING C Y, QIU L H. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis[J]. Gynecol Oncol, 2015, 139(2): 355-362.
doi: 10.1016/j.ygyno.2015.07.109
pmid: 26232517
|
[19] |
POWER L, LEFAS G, LAMBERT P, et al. Hormone use after nonserous epithelial ovarian cancer: overall and disease-free survival[J]. Obstet Gynecol, 2016, 127(5): 837-847.
doi: 10.1097/AOG.0000000000001396
pmid: 27054933
|
[20] |
ZHANG Y L, CHEN J H, LU W, et al. Efficacy of postoperative hormone replacement therapy on prognosis of patients with serous ovarian carcinoma[J]. Chin Med J (Engl), 2016, 129(11): 1316-1321.
|
[21] |
RAY-COQUARD I, MORICE P, LORUSSO D, et al. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4): iv1-iv18.
doi: 10.1093/annonc/mdy001
|
[22] |
DELI T, OROSZ M, JAKAB A. Hormone replacement therapy in cancer survivors-review of the literature[J]. Pathol Oncol Res, 2020, 26(1): 63-78.
doi: 10.1007/s12253-018-00569-x
|
[23] |
DEL CARMEN M G, RICE L W. Management of menopausal symptoms in women with gynecologic cancers[J]. Gynecol Oncol, 2017, 146(2): 427-435.
doi: S0090-8258(17)30954-X
pmid: 28625396
|
[24] |
REES M, ANGIOLI R, COLEMAN R L, et al. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis[J]. Maturitas, 2020, 134: 56-61.
doi: S0378-5122(20)30025-6
pmid: 32059825
|
[25] |
ANGIOLI R, LUVERO D, ARMENTO G, et al. Hormone replacement therapy in cancer survivors: utopia?[J]. Crit Rev Oncol Hematol, 2018, 124: 51-60.
doi: S1040-8428(17)30267-6
pmid: 29548486
|
[26] |
VARGIU V, AMAR I D, ROSATI A, et al. Hormone replacement therapy and cervical cancer: a systematic review of the literature[J]. Climacteric, 2021, 24(2): 120-127.
doi: 10.1080/13697137.2020.1826426
pmid: 33236658
|
[27] |
WANG J C M, BERNARD L, BOUTROSS-TADROSS O, et al. Estrogen receptor-positive adenocarcinoma of the cervix presenting during pregnancy: two case reports and review of the literature[J]. Gynecol Oncol Rep, 2022, 39: 100916.
|
[28] |
LEE S A, BAIK S, CHUNG S H. Functional roles of female sex hormones and their nuclear receptors in cervical cancer[J]. Essays Biochem, 2021, 65(6): 941-950.
|
[29] |
RICHARDSON A, WATSON L, PERSIC M, et al. Safety of hormone replacement therapy in women with a history of cervical adenocarcinoma[J]. Post Reprod Health, 2021, 27(3): 167-173.
doi: 10.1177/20533691211028518
|
[30] |
ADAMS T S, ROGERS L J, CUELLO M A. Cancer of the vagina: 2021 update[J]. Int J Gynaecol Obstet, 2021, 155(Suppl 1): 19-27.
|
[31] |
BUCCHI L, PIZZATO M, ROSSO S, et al. New insights into the epidemiology of vulvar cancer: systematic literature review for an update of incidence and risk factors[J]. Cancers (Basel), 2022, 14(2): 389.
doi: 10.3390/cancers14020389
|
[32] |
STUTE P, STADLER A, HEUFELDER A. The impact of menopausal hormone therapy on overall mortality-a comprehensive review[J]. Climacteric, 2020, 23(5): 447-459.
doi: 10.1080/13697137.2020.1767568
|
[33] |
PINKERTON J V. Hormone therapy for postmenopausal women[J]. N Engl J Med, 2020, 382(5): 446-455.
doi: 10.1056/NEJMcp1714787
|
[34] |
BABER R J, PANAY N, FENTON A, et al. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy[J]. Climacteric, 2016, 19(2): 109-150.
doi: 10.3109/13697137.2015.1129166
|
[35] |
US PREVENTIVE SERVICES TASK FORCE, GROSSMAN D C, CURRY S J, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US preventive services task force recommendation statement[J]. JAMA, 2017, 318(22): 2224-2233.
doi: 10.1001/jama.2017.18261
pmid: 29234814
|
[36] |
SIMIN J, TAMIMI R M, CALLENS S, et al. Menopausal hormone therapy treatment options and ovarian cancer risk: a Swedish prospective population-based matched-cohort study[J]. Int J Cancer, 2020, 147(1): 33-44.
doi: 10.1002/ijc.32706
pmid: 31584190
|
[37] |
VINOGRADOVA Y, COUPLAND C, HIPPISLEY-COX J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases[J]. BMJ, 2020, 371: m3873.
|
[38] |
KOTSOPOULOS J, GRONWALD J, KARLAN B Y, et al. Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers[J]. JAMA Oncol, 2018, 4(8): 1059-1065.
doi: 10.1001/jamaoncol.2018.0211
pmid: 29710224
|
[39] |
MARCHETTI C, DE FELICE F, BOCCIA S, et al. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis[J]. Crit Rev Oncol Hematol, 2018, 132: 111-115.
doi: S1040-8428(18)30276-2
pmid: 30447915
|
[40] |
VINOGRADOVA Y, COUPLAND C, HIPPISLEY-COX J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases[J]. BMJ, 2019, 364: k4810.
|
[41] |
LIANG Y, JIAO H Y, QU L B, et al. Association between hormone replacement therapy and development of endometrial cancer: results from a prospective US cohort study[J]. Front Med (Lausanne), 2021, 8: 802959.
|
[42] |
CRANDALL C J, HOVEY K M, ANDREWS C A, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study[J]. Menopause, 2018, 25(1): 11-20.
|